For pharma companies, the weeks immediately before and after FDA submission are critical to launch success. During this pivotal period, missteps can result in several undesirable outcomes at launch, from overestimating your brand’s adoption peak to underestimating the necessary contracting spend.
In this webinar, we’ll discuss five of the largest risks associated with launch. Our experts will explain the concrete steps your team can take to mitigate those risks in advance—so you can launch your therapy without fear of failure.
You will learn:
As a solution consultant for MMIT, Carolyn Zele helps pharmaceutical manufacturers simplify market access and prepare for launch success. Prior to MMIT, Carolyn spent numerous years in the payer/PBM space managing formulary teams and technology across both regulated and non-regulated lines of business. She holds a Master of Science degree from Colorado State University.
Alicia Heesen is a consultant on the Advisory Services team at MMIT. She works with pharmaceutical manufacturers of all sizes to resolve access challenges and support their market access strategies using MMIT’s data and market research. She earned a bachelor’s degree in biology from Seton Hall University.
Addie Blanchard is an associate manager on the PAR Insights team at MMIT. She brings data to life through analytics and storytelling, helping clients build competitive market access strategies and support the patient journey. She earned a bachelor’s degree in journalism at the University of Wisconsin – Madison and a master’s in public health from the University of Wisconsin – Milwaukee.
